Posted by Michael Wonder on 27 Jun 2023
More evidence needed to recommend type 2 diabetes treatment tirzepatide
27 June 2023 - More evidence is needed on the clinical and cost effectiveness of a new treatment option for patients with type 2 diabetes mellitus before it could be recommended for NHS use, a NICE committee has said.
Tirzepatide (Mounjaro, Eli Lilly), has not been recommended in draft guidance issued by NICE today for the treatment of adults with type 2 diabetes mellitus alongside diet and exercise.
